, , ,

<<


 >>  ()
Pages:     | 1 |   ...   | 3 | 4 ||

.. ...

-- [ 5 ] --

11) Friedman, SL. 2003. Liver fibrosis from bench to bedside. Journal of Hepatology 38: S38S53.

12) Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. 1997. Morbidity and mortality in com pensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112:463472.

13) Rehm, J, Rehn, N., Roome R, Monteiro M, Gmelg G, Jernigan D., & Ulrich F. 2003. The Global Distribution of Average Volume of Alcohol Consumption and Patterns of Drinking. Eur Addict Res 9:147156.

14) Hibell B, Andersson B, Ahlstrm S, Balakireva O, Jarnasson T, Kokkevi A, et al: 2000. The 1999 ESPAD Report.

Alcohol and Other Drug Use among Students in 30 European Countries. Stockholm, Pompidou Group, Council of Europe.

15) Jernigan DH. 2001. Global Status Report: Alcohol and Young People. Geneva, WHO.

16) Rehn, N., Room, R. & Edwards, G. (2001) Alcohol in the European Region consumption, harm and policies (Co penhagen, WHO Regional Office for Europe).

17) Grant BF. Hartford TC. Dawson DA, Chou, P, DuFour, M, & Pickering R. 1994. Prevalence of DSMIV alcohol abuse and dependence: United States, 1992. Alcohol Health & Research World 18:243248.

18) Lieber CS 1993. Alcoholic liver disease: a public health issue in need of a public health approach. Semin. Liver Dis ease 13: 105107.

19) Gutjahr E, Gmel G, & Rehm J. 2001. Relation between average alcohol consumption and disease: An overview. Eur Addict Res. 7:117127.

20) Ezzati M, Lopez AD, Rodgers A, Vander Horn S, Murray CJL, and the Comparative Risk Assessment Collaborating Group. 2002. Selected major risk factors and global and regional burden of disease. Lancet 360:13471360.

21) Rehm J, Broome R, Monteiro M, Gmel G, Graham K, Rehn N, Sempos CT, Jernigan D. 2003. Alcohol as a Risk Factor for Global Burden of Disease, Eur. Addict. Res. 9:157 22) Stewart, SF& Day CP. 2003. Management of alcoholic liver disease. Journal of Hepatology, 38(Supp 1. 1) :S2-S13.

23) Alcohol Related Liver Disease Working Party, British Liver Trust, at http://www.britishlivertrust.org.uk, last accessed 6 June 2004.

24) Kim WR, Grown RS Jr, Terrault NA, El-Serag H. 2002. Burden of liver disease in the United States: Summary of a workshop, Hepatology 36: 227-242.

25) Szabo, G. 1999, Consequences of Alcohol Consumption on Host Defense, Alcohol & Alcoholism, 34: 830-841.

26) Baker, R.C. & Jerrells, TR. 1993. Recent developments in alcoholism: Immunological aspects. Recent Dev Alcohol 11:249271.

27) MacGregor RR & Louria DB. 1997. Alcohol and infection Curr Clin Top Infect Dis. 17:291315.

28) Centers for Disease Control and Prevention. Reported Tuberculosis in the United States:Surveillance Report 1996.

Atlanta, GA: Division of Tuberculosis Prevention, National Center of Infectious Diseases, Centers for Disease Con troland Prevention.

29) Friedman LN, Williams MT, Singh TP, & Frieden TR. 1996. Tuberculosis, AIDS, and death among substance abus ers on welfare in New York City. N Engl J Med 334: 828833.

30) Cortese MM, Wolff M, Almeido-Hill J, Reid R, Ketcham J & Santosham M. 1992. High incidence rates of inva sive pneumococcal disease in the White Mountain Apache population. Arch Intern Med 152:22772282.

31) Esposito AL. 1984. Community-acquired bacteremic pneumococcal pneumonia: Effect of age on manifestations and outcome. Arch Intern Med 144: 945948.

32) Kuo CH, Changchien CS, Yang CY, Sheen IS & Liaw YF. 1991. Bacteremia in patients with cirrhosis of the liver.

Liver 11:334339.

33) Koff RS & Dienstag JL. 1995. Extra hepatic manifestations of hepatitis C and the association with alcoholic liver disease. Seminars in Liver Disease 15:101-109.

34) Rosman AS, Paronetto F, Galvin K, Williams RJ, & Lieber CS. 1993. Hepatitis C virus antibody in alcoholic pa tients: Association with the presence of portal and/or lobular hepatitis. Arch Intern Med. 153: 965-969.

35) Ostapowicz G, Watson KJR, Locarnini SA, & Desmond PV. 1998. Role of alcohol in the progression of liver dis ease caused by hepatitis C virus infection. Hematology 27:1730- 36) Corrao G & Arico S. 1998. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hematology 27:914-919.

37) OConnell H, Chin A-V, Cunningham C, Lawlor B. 2003. Alcohol use disorders in elderly peopleredefining an age old problem in old age BMJ 327:664667.

38) Johnson I. 2000. Alcohol problems in old age: a review of recent epidemiological research. Int J Geriatr Psychiatry 15:575-81.

39) Reid MC & Anderson PA. 1997. Geriatric substance use disorders. Med Clin North Am 81:999-1016.

40) Curtis JR, Geller G, Stokes EJ, Levine DM, & Moore RD. 1989. Characteristics, diagnosis, and treatment of alcohol ism in elderly patients. J Am Geriatr Soc 37:310-316.

41) Williams R & Horm J. 1977. Association of cancer sites with tobacco and alcohol consumption and socioeconomic status of patients: Interview study from the Third National Cancer Survey. J Natl Cancer Inst 58:525547.

42) Holman C, English D, Milne E, & Winter E. 1996. Meta-analysis of alcohol and all-cause mortality: A validation of NHMRC recommendations. Med J Aust 164:141145.

43) Smith-Warner S, Spiegelman D, Yaun S, van den Brandt P, Folsom A, Goldbohm A, Graham S, Holmberg L, Howe G, Marshall J, Miller A, Potter J, Speizer F, Willett W, Wolk A, & Hunter D. 1998. Alcohol and breast cancer. JAMA 279:535540.

44) Katsouyanni K, Trichopoulos A, Stuver S, Vassilaros S, Papadiamantis Y, Bournas N, Skarpov N, Mueller N & Trichopoulos D. 1994. Ethanol and breast cancer: An association that may be both confounded and causal. Int J Cancer 58:356361.

45) Roth H & Levy P. 1995. Alcohol and breast cancer response. J Clin Epidemiol 48:498500.

46) Becker U, Deis A, Sorensen TI, Gronbaek M, Borch-Johnsen K, Muller CF, Schnohr, P, & Jensen G. 1996.

Prediction of risk of liver disease by alcohol intake, sex and age: A prospective population study. Hepatology 23:10251029.

47) Arthur MJ., Lee A & Wright R. 1994. Sex differences in the metabolism of ethanol and acetaldehyde in normal subjects. Clin Sci 67:397401.

48) Loft S, Olesen KL, & Dossing M. 1987. Increased susceptibility to liver disease in relation to alcohol consumption in women. Scand J Gastroenterology ;

22:1251-1256.

49) Tsuang MT, Lyons MJ, Eisen SA, Goldberg J True W, Lin N, Meyer JM, et al. 1996. Genetic influences on DSM III-R drug abuse and dependence: a study of 3,372 twin pairs. Am J Med Genet. 67:473477.

50) Schuckit MA & Smith TL. 1996. An 8-year follow-up of 450 sons of alcoholic and control subjects. Arch Gen Psy chiatry. 53:20210.

51) Monzoni A, Masutti F, Saccoccio G, Bellentani S, Tiribelli C & Giacca M. 2001. Genetic determinants of ethanol induced liver damage. Mol Med. 7:255262.

52) Jarvelainen HA, Orpana A, Perola M, Savolainen VT, Karhunen PJ & Lindros KO. 2001. Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease Hepatology 33:114853.

53) Rosenberg W, Becka BA, Voelker M, Arthur MJP. 2000. Automated assays of serum markers of liver fibrosis pre dict histological hepatic fibrosis. Hepatology 32:183A.

54) Anni, H., et al, 2003. Alcoholism: Clinical and Experimental Research 27:1613-1621.

55) Fuller RK & Gordis E. 2004. Does disulfiram have a role in alcoholism treatment today? Addiction. 99: 21-24;

Rez vani AH, Overstreet DH, Mason GA, Janowsky D, Hamedi M, Clark E., & Yang Y. 2000. Combination pharma cotherapy: A mixture of Small Doses of Naltrexone, Fluoxetine and a thyrotropin-releasiong hormone reduces alcohol intake in three strains of alcohol preferring rats. Alcohol & Alcoholism Vol. 35, No. 1, pp. 7683, 56) Volpicelli, J R., Alterman, A I., Hayashida, M. & OBrien C P. 1992. Naltrexone in the treatment of alcohol depen dence. Archives of General Psychiatry 49, 876880.

57) Pucilowski, O., Rezvani, A H. & Janowsky, D.S. 1992. Suppression of alcohol and saccharin preference in rats by a novel Ca2+ channel inhibitor, GOE 5438. Psychopharmacology 107, 447452.

58) Hodge C A., Haraguchi M., Erickson H L. & Samson H H. 1993. Ventral tegmental microinjections of quinpirole decrease 59) ethanol and sucrose-reinforced responding. Alcoholism: Clinical and Experimental Research 17, 370375.

60) Hodge C A., Samson, H H., Lewis R S. & Erickson, H L. 1993. Specific decreases in ethanol but not water reinforced responding produced by the 5-HT3 antagonist ICS 205930. Alcohol 10: 191196.

61) Rezvani AH & Janowsky, D S. 1990. Decrease of alcohol consumption by verapamil in alcohol preferring rats.

Progress in Neuro-Psychopharmacology and Biological Psychiatry 14, 623631.

62) McBride W J., Murphy J M., Lumeng L & Li T.-K. (1990. Serotonin, dopamine and GABA involvement in al cohol drinking of selectively bred rats. Alcohol 7, 199205.

63) Alexander JF, et al. 1971. Natural history of alcoholic hepatitis. Am J. Gastroenterol. 56:515525.

64) Pares A, et al. 1986. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic dam age. J Hepatol 2:3342.

65) Orrego H, et al. 1987. Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis. Gastroen terology 92:208214.

66) Stewart S, et al. 2001. Alcoholic liver disease: new insights into mechanisms and preventative strategies. Trends Mol Med 7:408413.

67) Tsukamoto H & Lu SC. 2001. Current concepts in the pathogenesis of alcoholic liver injury. FASEB J 15:1335 1349.

68) Imperiale TF & McCullough AJ. 1990. Do corticosteroids reduce mortality from alcoholic hepatitis? a meta analysis of the randomized trials. Ann Intern Med. ;

113:299-307.

69) Christensen E & Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for con founding variables. Gut. 37:113-118.

70) Carithers RL Jr, Herlong HF, Diehl AM, et al. 1989. Methylprednisolone therapy in patients with severe alcoholic hepatitis: a randomized multicenter trial. Ann Intern Med. 110:685- 71) Mendenhall CL, Anderson S, Garcia-Pont P, et al. 1985. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med. 311:1464-1470.

72) McClain CJ, Barve S, Barve S, Deaciuc I, & Hill DB. 1998. Tumor necrosis factor and alcoholic liver disease. Al cohol Clin Exp Res. 2(5, suppl):248S-252S.

73) Faubion WA, & Gores GJ. 1999. Death receptors in liver biology and pathobiology. Hepatolog 29:1 ??

74) Felver ME, Mezey E, McGuire M, et al. 1990. Plasma tumor necrosis factor alpha predicts decreased long-term sur vival in severe alcoholic hepatitis. Alcohol Clin Exp Res. 14:255-259.

75) Iimuro Y, Gallucci RM, Luster MI, Kono H, & Thurman RG. 1997. Antibodies to tumor necrosis factor alfa attenu ate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology. 26:1530-1537.

76) Iimuro Y, Gallucci RM, Luster MI, Kono H, & Thurman RG. 1997. Antibodies to tumor necrosis factor alfa attenu ate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 26:1530-1537.

77) Kono H, Rusyn I, Yin M, et al. 2000. NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. J Clin Invest. 106:867-872.

78) Halle P, Pare P, Kaptein E, Kanel G, Redeker AG, & Reynolds TB. 1982. Double-blind, controlled trial of propyl thiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology. 82(5, pt 1):925-931.

79) Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, & Shakil O. 2000. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 119:1637-1648.

80) Heemann U, et al. 2002. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 36:949958.

81) Carini R, et al. 1992. Lipid peroxidation and irreversible damage in the rat hepatocyte model. Protection by the sily binphospholipid complex IdB 1016. Biochem Pharmacol. 43:21112115.

82) Mato JM, et al. 1999. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double blind, multicenter clinical trial. J Hepatol 30:10811089.

83) Orrego H, et al. 1987. Long-term treatment of alcoholic liver disease with propylthiouracil. N Engl J Med 317:14211427.

84) Kershenobich D, et al. 1998. Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 318:17091713.

85) Rambaldi A & Gluud C. 2001. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Da tabase Syst Rev 3.

86) Starzl TE, et al. 1988. Orthotopic liver transplantation for alcoholic cirrhosis. J Am Med Assoc 260:25422544.

87) Belle SH, et al. 1997. Liver transplantation for alcoholic liver disease in the United States: 1988 to 1995. Liver Transpl Surg 3:212219.

88) Wiesner RH, et al. 1997. Liver transplantation for end-stage alcoholic liver disease: an assessment of outcomes.

Liver Transpl Surg 3:231239.

89) Bird GL, et al. 1990. Liver transplantation in patients with alcoholic cirrhosis: selection criteria and rates of survival and relapse. Br Med J 301:1517.

90) Gerhardt TC, et al. 1996. Alcohol use following liver transplantation for alcoholic cirrhosis. Transplant Proc 62:10601063.

91) Pageaux GP, et al. 1999. Alcoholic cirrhosis is a good indication for liver transplantation, even for cases of recidi vism. Gut 45:421426.

92) Neuberger J, et al. 1998. Assessing priorities for allocation of donor liver grafts: survey of public and clinicians. Br Med J 317:172175.

93) Heffler S, Levit K, Smith S, Smith C, Cowan C, Lazenby H, & Freeland M. 2001. Health spending growth up In 1999: faster growth expected in the future. Health Affairs. 20:193-202.

94) Room R: 1992. The impossible dream? Routes to reducing alcohol problems in a temperance culture. J Subst Abuse 4:91106.

95) Foxcroft DR, Ireland D, Lister-Sharp DJ, Lowe G, & Breen R. 2003. Longer-term primary prevention for alcohol misuse in young people: A systematic review. Addiction 98:397 96) Diehl AM. 1998. Alcohol and liver regeneration. Clin Liver Dis. 2 723-738.

97) Alison MR. 2003. Liver regeneration with reference to stem cells. Sem. Cell & Dev. Biol. 13: 385-387.

98) Mason BJ et al. 1999. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch. Gen.

Psy. 56: 719-724.

99) Lovinger D. Serotonin's role in alcohol's effects on the brain. 1997. Alcohol Health and Res World. 21:114-120.

100) Cornelius JR, Salloum IM, et al. 1997. Fluoxetine in depressed alcoholics. A double-blind placebo controlled trial.

Arch Gen Psychiatry. 54:700-705.

101) Johnson BA, Roache J, et al. 2000. Ondansetron for reduction of drinking among biologically predisposed patients:

a randomized controlled trial. JAMA. 284:963-971;

Kranzler HR, Pierucci-Lagha A, et al. 2003. Effects of ondanse tron in early- versus late-onset alcoholics: a prospective, open-label study. Alcohol Clin Exp Res. 27:1150-1155.

102) Fawcett J, Kravitz HM, et al. 2000. Pharmacological treatments for alcoholism: revisiting lithium and considering buspirone. Alcohol Clin Exp Res. 24:666-674.

103) Modell JG, Mountz JM, et al. Effect of haloperidol on measures of craving and impaired control in alcoholic sub jects. 1993. Alcohol Clin Exp Res. 17:234-240;

Shaw GK, Waller S, et al. 1994. Tiapride in the prevention of relapse in recently detoxified alcoholics. Br J Psychiatry.1994;

165:515-523;

Hutchinson K, Swift R, et al. 1998. Effects of olanzapine on cue induced craving in moderate to heavy social drinkers. Alcohol Clin Exp Res. 22: 662A;

Drake RE, Xie H, et al. 2000. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia.

Schizophr Bull.26:441-449.

104) Johnson BA, Ait-Doud N, et al. 2003. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 361:1677-1685.

105) Johnson BA, Ait-Doud N, Prihoda, TJ. 2000. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypothesis to preliminary clinical evidence. Alcohol Clin Exp Res. 24:737-742.

106) National Institute on Alcohol and Alcohol Abuse http://www.niaaa.gov, last accessed 12 May 2004.

107) Iredale JPO. 2003. Science, medicine, and the future Cirrhosis: new research provides a basis for rational and tar geted treatments. BMJ 327:143-147.

108) NIH clinical trials website, at http://www.clinicaltrials.gov, last accessed 3 June 2004.

109) LaBonte, J and DeVasher C., 2004. Hepatitis C Virus, Decision Resources Market report, at http://www.dresources.com, last accessed 8 June 2004.

110) Pawlotsky J-M & McHutchinson JG. 2004. Hepatitis C. Development of new drugs and clinical trials: Promises and pitfalls, Hepatology 39: 554-567.

111) United States Cancer Statistics, available at http://www.cdc.gov, last accessed 10 May 2004.

III. 2004 1) 21.05.2003 .

2) European Alcohol Action Plan, 2000-2005/ 2000-2005 .

3) Adequacy in Drug Abuse Treatment and Care in Europe (ADAT), Zurich, 2000.

4) Herald Klingemann. . , 2001.

5) Alcohol Consumption and Alcohol-related Problems: Development of National Policies and Programmes.

WHA36.12.

6) 12-14.12.1995 .

7) Alcohol and Crime, Institute of Alcohol Studies (UK).

8) Alcohol and the Elderly, Institute of Alcohol Studies (UK).

9) Binge Drinking, Institute of Alcohol Studies (UK).

10) Drinking and Driving, Institute of Alcohol Studies (UK).

11) Alcohol Consumption and Harm in the UK and EU, Institute of Alcohol Studies (UK).

12) Alcohol and You, Institute of Alcohol Studies (UK).

13) / 2001 , .

14) . . ., 1999.

15) .. / . .--, 2000.

16) ., . : ! , 2001.

17) . : . ,2002.

18) . , . , 2002.

19) / . . .. .- ., 2001.

20) . ( ). ., 2001.

21) . . , 1995.

22) . : .- , 1995.

23) .. . . ., 1999.

24) . (The Language of Letting Go)/ 25) ( , ..). N.-Y., 1997.

26) . Nar-Anon Family Group, Inc., 1971.

27) ( . 1989.

28) ( ). , 2001.

29) .

30) (- )/ . . . ..

. .. .- ., 1994.

31) - (. ). ., 1991.

32) (. )/ . . .. .

., 1991.

33) .. , , , . , 2000.

34) .. . .--, 2002.

35) .., .. 1998 / . ., 2000.

36) .. . ., 1999.

37) (). . ., 2000.

38) .., .. . ., 2000.

39) .., .. . , 1998.

40) .. / . ., 1997.

41) . (, ). , 2000.

42) .., .. . ., 2001.

43) . , ! , 2001.

44) .., .. / . ., 2000.

45) .., .. : , , . , 2000.

46) . ( ). . , 1999.

47) ( .., ..). - ., 1995.

48) . . . ., 1999.

49) .. . ., 1994.

50) .. - . ., 2001.

51) . ., . . / . . , 2004.

52) .. / . - , 1998.

53) : / . .. . ., 1989.

54) Declaration on Young People and Alcohol, 2001.

55) , 1997. , , 1997.

, 1, 2, 5, 7, 8, 9, 66, 74, 86, 89, 94, 101, 103, 110, 117, 121, 126, 130, 131, , 1, 3, 5, 6, 7, 8, 9, 11, 12, 66, 67, 68, 74, 75, 76, 77, 83, 84, 86, 87, 88, 90, 91, 94, 96, 97, 98, 99, 100, 102, 103, 104, 105, , 106, 107, 108, 110, 111, 112, 113, 114, 115, 116, 117, 119, , 30, 43, 45, 78, 115, 138, 120, 121, 122, 123, 124, 136, 137, 140, 141, , 30, 31, 33, 34, 36, 41, 45, 51, 78, 111, 115, , 9, 31, 36, , 1, 114, 130, 131, 136, , 1, 7, , 119, 120, , 2, 6, 122, 123, 130, , , 113, , , 43, 75, 78, , , 7, 36, 37, 52, 64, 65, 115, 119 , , 54 , 5, 61, 83, 84, 108, 128, 136, , 83, , 8, 74, 130, , 37, 38, 62, 66, 69, 71, 116, 117, 119, 120 , 14, 33, , 5, 9, 11, 40, 41, 64, 115, 116, 117, 119, 120, , 122, 123 , , , 66, 78, 88, 102, 105, 107, 110, , 36 , 1, 2, 3, 5, 6, 9, 11, 66, 67, 68, 88, 91, 94, 103, 105, 107, 108, 110, 114, 123, 130, 131, 136, , 18, 21, 22, 24, 27, 34, 35, 42, 43, 49, 56, 58, 68, 69, 70, 75, 76, 86, 88, 94, 100, 103, 107, 108, 110, 111, 113, 115, , 66, 89, 94, 101, 103, 117, 121 119, , 66, 89, 94, 101, 103, 117, , 13, 25, 27, , 1, 2, 3, 5, 6, 9, 11, 28, 32, 34, 36, 37, 38, 40, 41, 42, 44, 45, 46, 52, 53, 55, 62, 64, 66, 67, 68, 75, 76, 77, 83, 85, 91, 96, 99, 100, 101, 103, 105, 106, 107, 108, 110, 111, 112, 114, 115, 117, 118, 119, 122, 126, 130, 131, .. , .. , 136, 138, 140, 141, , 1, 2, 7, , , 1, 2, 7, , , 94, 103 , 1, 2, 9, 12, 85, 124, 130, 131, , 56 136, 141, , 2, 3, 12, 126, 127, 129, 130, 136, 140, 141, , , 148 , 6, 123, .................................................................................................................................. ............................................................................................................ ......................................................................................................................... ..................................................................................................................................................................... .................................................................................................................................... ................................................................................................. I. : ................................. .............................................................................................................................................................................. ?................................................................................................ ............................................................................................................................... ?...................................................................................................................................... ........................................................................................ .................................................................................. ............................................................... ...................................................................................................... ............................................................................................................... ............................................................................................. ..................................................................................................................................... , ............................................................................... .................................................................... ....................................................................................................... . ........................................................................................................................................................... . .......................................................................................................................................................... ................................................................. / ................................................................................................................................................. II. : .................................................................................. .................................................................................................................................................................................. ................................................................................................................................................................. ................................................................................................................................................................. 1. .......................................................................................................................................................................... 1.1 ......................................................................................................................................... 1.2 ............................................................................................................................. 1.2.1 ........................................................................................................................................... 1.2.2 ........................................................................................................................................................... 1.2.3 ............................................................................................................................................................ ................................................................................ 1.3.1 DSM...................

.................................................................................................................................................. 1.3.2 ICD....................................................................................................................................................................... 2. .................................................................................................. 2.1 ......................................................................................................................................................................... 2.1.1 .................................................................................................................. 2.1.2 .......................................................................................................................................................... 2.2 ....................................................................................................................... 2.3 ......................................................................................................................................................... 2.3.1 ....................................................................................................................... 2.3.2 ....................................................................................................................................................... 2.3.3 ................................................................................................................................................................... 2.3.4 ...................................................................................................................................................... 2.3.5 .................................................................................................................................... 2.3.6 , ............................. 3. ?....................................................................................................................................... 3.1 ......................................................................................................................... 3.2 ()................................................................................................................... 3.2.1 ().................................................................................................................................................. 3.2.1.1 (TNF-alpha)............................................................................................................ 3.2.1.2 ................................................................................ 3.2.1.3 .................................................................................................................................................... 3.2.2 ............................................................................................................................................................ 3.2.2.1 ........................................................................................................................................................... 3.2.2.2 ()............................................................................................................................................ 3.2.2.3 ..................................................................................................................................................................... 3.3 ........................................................................................................................................................ 4. , ?........................... 4.1 ............................................................................................................................................. 4.2 ...................................................................................................................... 5. ......................................................................... 6. / ?.......................................................................................................................................................................... 6.1 .............................................................................................................................................................. 6.2 ............................................................................................................................................ 7. Ż , ?............................................................................................................................................................ 7.1 ........................................................................................................................................ 7.1.1 ........................................................................................................................................................ 7.1.2 ........................................................................................................................................ 7.1.3 ........................................................................................................................................... 7.1.4 ................................................................................................................................................ 7.2 .......................................................................................................................................... 7.3 .............. 8. ?............................................................................................................................................................................... 8.1 .....................................................................................................................

........................ 8.1.1 : ............................... 8.1.1.1 .......................................................................................................................................................... 8.1.1.2 ...................................................................................................................................................... 8.1.2 ....................................................................................................... 8.2 ................................................................................................................... 9. .................... 9.2 , ................................................................................................................................................... 9.1.1 ........................................................................................................................................ 9.1.2 .................................................................................................................................................. ......................................................................................................................................................................... III. , 2004 ...................................................................................................... ................................................................................... ................................................................................................................................ ............................................................................................................................ - ......................................................................................................... ........................................................................................................................... ..................................................................................................................................................... , , ......... ........................................................................................................................................... ....................................................................................................................................................................... ...................................................................................................................................................... ................................................................................................................................................................. ............................................. ........................................................................... .................................................. ............................................................................................................................................................................ ..................................................................................................................................................................... , ........................................................................ , ............................................................................................. .................................................................................................................... ................................................................................................................................................. ......................................................................................... ............................................................................................................................ ............................................................................................................................................................ ........................................................................................................................... . ...................................................................................................................................................... . ................................................................................................................................................... . ............................................................................................................................................................................ . ..................................................................................................................................................................... . .................................................................................................................................................. . .................................................................................................................................................... . ......................................................................................................................... . ...................................................................................................................... . ........................................................................................................................................... . ................................................................................................................................................. . ............................................................................................................................................................ ........................................................................................................... ..............................................................

............................................................................................ ........................................................................................................... . ..................................................................................................................................... . ....................................................................................................................... . ................................................................................................................................................ . ......................................................................................................................................... . ...................................................................................................................... . ........................................................................................................................ . ............................................................................................. . ........................................................................................................................... . ...................................................................................................................... . ................................................................................................................................ - ....................................... ........................................................................................................................................ ...................................................................................................................................................................................... ........................................................................................................................................................................................ ............................................................................................................................................................. ........................................................................................................................................................ .......................................................................................................................................................................... .............................................................................................................................................. ........................................................................................................... ................................................................................ ..................................................................... .......................................................................................................................................................................... ................................................................................................................................................................... IV. - ......................................................... ............................................................................................................................................................................. .............................................................................................................................................. ............................................................................................................................................ ............................................................................................................................................. ........................................................................................................................................................... , .................................................................................................................. , ......................................................................................................................... ............................................................. : 21 ............................................................................................................................................................................................. ............................................................................................................................................................. ....................................................................................................................................................... ............................................................................................................................................. ........................................................................................................................................................ .............................................................................................................. .......................................................... ............................................ .................................................................................................................................................................. ................................................................................................................................ ............................................................................................................................................ ߻.............................. ................................................. .................................................................................................. ........................................................................................................................ ..................................................................................................................... ..................................................................................................................... ........................................................................................................................................................................ I. : ................................................................... II. : ................................................................................................................................................................ III. 2004 ............ ................................................................................................................................................... ...................................................................................................................... Summary............................................................................................................................ Zusammenfassung............................................................................................................. Summary Sobriety and lack of any dependency is fashionable in the progressive world. Unhealthy customs are being noted by employers announcing a va cancy, because they care about prosperity of their enterprises and about well being of workers.

In Russia as a whole and in Industrial Region Norilsk (IRN) in particular there is an epidemic of tobacco and alcohol use. Deduction about pandemic in IRN are made on the base of a first epidemiological investigation of able bodied inhabitants.

The main achievement of this study is showing indication for primary and secondary prevention of alcohol and tobacco use have about 66,7% of IRN in habitants, that makes ca 160 thousand people. The secondary prevention only in consequence of tobacco use have ca 171 thousand people, of alcohol use ca 215 thousand people. The primary prevention is necessary only for 5,8% of all IRN inhabitants, that is 14 thousand people. So the object of preventive ac tivity is to be all the IRN inhabitants without exceptions, every man and every woman of any age, of any IRN life and work longitude, of all education stages and marital status.

In this book are included made first in Russia translations into Russian of background papers for WHO report Priority Medicines for Europe and the World A Public Health Approach to Innovation, written by Warren Kaplan Alcohol Use Disorders: Alcoholic Liver Diseases and Alcohol Dependency (7th October 2004) and Tobacco Use Cessation: Importance and Implica tions (12th October 2004). As an example of used in the Center of Mental Healths social activity is included a translation of a booklet Parenting Skills:

21 Tips & Ideas to Help You Make a Difference, that is issued by Office of National Drug Control Policy (USA).

This book can be of interest for public health specialists, managers of pharmaceutical industry, sociologists, educational specialists, employers, poli tologists, policy makers and unrestricted readers in IRN and other regions in Russia.

This book is being a first part of a fundamental original research that has a working name Morbus Norilski.

This monograph contains 160 pages;

10 graphs, 30 tables;

1 scheme;

200 literature references, including 44 in Russian and 156 in foreign languages;

foreword, 4 parts, afterword;

a yellow cover with a photograph.

Zusammenfassung Die Nchternheit und Ruschgiftanhngigkeitmangel ist modisch in der modernen Welt. Schdiche Gewohnheiten ziehen Aufmerksamkeit der Arbeitgeber, die fr Gedeihen ihren Betrieben und Gesundheit ihren Arbeitern sorgen, an.

In Ruland insgesamt und, unter anderem, in der Norilsks Industrieregion (NIR), wir beobachten eine Epidemie der Alkohol- und Tabakeinnahme.

Schlufolgerungen ber eine Pandemie in NIR sind auf Grund der ersten in NIR epidemiologischen Untersuchung der arbeitsfhigen Bewohnern getan.

Der Haupterfolg dieser Untersuchung ist eine Vorfhrung, da primre und sekundre Alkohol-und Tabakeinnahme Vorbeugungzeugnisse etwa 66,7% (160 Tausend) der NIR-Bewohner haben. Die sekundre Tabakeinnahme Vorbeugungzeugnisse haben etwa 171 Tausend Bewohner und die sekundre Alkoholeinnahme Vorbeugungzeugnisse ziegen etwa Tausend Bewohner. Die primre Vorbeugung ist nur fr etwa 5,8% ( Tausend) der NIR-Bewohner ntig. Solcherweise alle NIR-Bewohner sollen ein Objekt der Vorbeugung werden, ausnahmslos, von allen ltern, allen Geschlechts, allen in NIR Arbeit- und Lebensdauern, mit allen Bildungen und Familienstnden.

In diesem Buch sind folgende erste in Ruland gemachte bersetzungen ins Russische eingeschlossen: Priority Medicines for Europe and the World A Public Health Approach to Innovation von Warren Kaplan Alcohol Use Disorders: Alcoholic Liver Diseases and Alcohol Dependency (7. October 2004) und Tobacco Use Cessation: Importance and Implications (12.

October 2004). Als ein Beispiel der benutzenden in Arbeit des Zentrums der Psychischen Gesundheit ist eine bersetzung des Bchleins Parenting Skills:

21 Tips & Ideas to Help You Make a Difference, da von Office of National Drug Control Policy (USA) ausgegeben ist, angefhrt.

Dieses Buch kann fr Gesundheitswesenspezialisten, Leitern der pharmazeutischen Industrie, Soziologen, Lehrern, Politiker und unbegrenzten Leserzirkel interessant sein.

Dieses Buch ist der erste Teil einer grndlichen wissenschaftlichen Forschung mit Arbeitsname Morbus Norilski.

Diese Monographie enthaltet 160 Seiten;

10 graphischen Darstellungen, 30 Tabellen;

1 Schemas;

200 Literaturverweisen, mit 44 in Russisch and 156 in auslndischen Sprachen;

Vorwort, 4 Kapitels, Nachwort;

einen gelben Umschlag mit einem Foto.

Die Pandemie und Vorbeugung der Alkohol- und Tabakeinnahme in Norilsk, Talnah und Kayerkan die Alkohol- und Tabakeinnahmesituation und schwerwiegende Folgen in der Welt die Ergebnisse der Norilsk-, Talnah-, Kayerkanbewohnerberprfung in 2004 und ofizielle Statistik von 1998- die Besonderrisikogruppen die Vorbuegungprogramm fr NPR das Zentrum der Psychischen Gesundheit Norilsk, Pandemic & Prevention of Alcohol- and Tabak Use to Norilsk, Talnah and Kayerkan Global Alcohol and Tabacco Use Disorders Outcome of Norilsk, Talnah, Kayerkan Inhabitants Examination in 2004 und Formal Statistics for 1998- NPR Groups of High Disease Burden Risks Prevention Programm for NPR The Center of Mental Health Norilsk, ߻

nakamuta@nakamuta.org -, 1 Ļ . 2004 , ,

Pages:     | 1 |   ...   | 3 | 4 ||
 
 >>  ()





 
<<     |    
2013 www.libed.ru - -

, .
, , , , 1-2 .